FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.534,76 +672,13 (+1,14%)
Trex Wind-down, Inc. (BPC.F)
| Chiusura precedente | 0,2920 |
| Aperto | 0,2920 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,2920 - 0,2920 |
| Intervallo di 52 settimane | 0,2800 - 2,9200 |
| Volume | |
| Media Volume | 10 |
| Capitalizzazione | 1,002M |
| Beta (5 anni mensile) | -1,60 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8100 |
| Prossima data utili | 29 apr 2024 - 05 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the NYSE American LLC (the “NYSE American”) has accepted the Company’s business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii)
- GlobeNewswire
Timber Pharmaceuticals to be Acquired by LEO Pharma
Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through Contingent Value RightsTotal Transaction Value of up to $36 millionTransaction Expected to Close in the 4th Quarter of 2023, subject to closing conditions and stockholder approval WARREN, NJ, Aug. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR) today announced that it has entered into a definitive agreement to be acq
- GlobeNewswire
Timber Pharmaceuticals Discloses Communication From NYSE American
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that on June 28, 2023 it received a letter (the “Notice”) from the NYSE American LLC (“NYSE American” or the “Exchange”) advising the Company is not in compliance with the NYSE American cont
